TELA · Insider Trading
TELA Bio, Inc. Common Stock
Every open-market purchase and sale reported by TELA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-19 | William J. Plovanic | Director | A | +16,089 | +$16.25K |
| 2026-10-19 | Joseph H Capper | Director | A | +19,801 | +$20.00K |
| 2026-09-18 | Joseph H Capper | Director | Buy | +75,000 | +$88.80K |
| 2026-09-16 | Joseph H Capper | Director | Buy | +75,000 | +$78.44K |
| 2026-08-19 | Heather C Getz | Chief Executive Officer | Buy | +12,500 | +$8.31K |
| 2026-08-17 | Heather C Getz | Chief Executive Officer | Buy | +15,000 | +$10.47K |
| 2026-08-05 | Heather C Getz | Chief Executive Officer | A | +500,000 | — |
| 2026-07-17 | William J. Plovanic | Director | A | +20,930 | +$16.43K |
| 2026-07-17 | Joseph H Capper | Director | A | +6,227 | +$4.89K |
| 2026-06-11 | Joseph H Capper | Director | A | +23,600 | — |
| 2026-06-11 | William J. Plovanic | Director | A | +11,675 | — |
| 2026-06-11 | Paul Thomas | Director | A | +23,600 | — |
| 2026-06-11 | Guido J Neels | Director | A | +23,600 | — |
| 2026-06-11 | Betty Jo Rocchio | Director | A | +11,675 | — |
| 2026-06-11 | Guy P Nohra | Director | A | +23,600 | — |
| 2026-02-24 | Megan Smeykal | Chief Accounting Officer | MIXED | +30,042 | −$2.10K |
| 2026-02-24 | Gregory A. Firestone | Chief Business Officer | MIXED | +31,459 | −$4.04K |
| 2026-02-24 | Roberto Cuca | COO and CFO | MIXED | +46,986 | −$7.44K |
| 2026-02-24 | Jeffrey Blizard | President | A | +86,000 | — |
| 2026-02-24 | Antony Koblish | Chief Executive Officer | MIXED | +147,975 | −$20.93K |
| 2026-02-24 | Paul Talmo | Chief Technology Officer | MIXED | +49,554 | −$5.54K |
| 2025-11-17 | EW HEALTHCARE PARTNERS FUND 2-A, L.P. | 10%+ Owner | Buy | +14,416,000 | +$16.00M |
| 2025-11-03 | William J. Plovanic | Director | A | +11,925 | — |
| 2025-10-10 | Betty Jo Rocchio | Director | A | +11,925 | — |
| 2025-08-05 | Gregory A. Firestone | Chief Commercial Officer | F | −1,093 | −$2.03K |
| 2025-06-02 | Jeffrey Blizard | President | A | +104,800 | — |
| 2025-05-30 | Vincent J Burgess | Director | A | +7,950 | — |
| 2025-05-30 | Jeffrey Blizard | Director | A | +7,950 | — |
| 2025-05-30 | Lisa N Colleran | Director | A | +7,950 | — |
| 2025-05-30 | Federica F. O'Brien | Director | A | +7,950 | — |
| 2025-05-30 | Kurt Azarbarzin | Director | A | +7,950 | — |
| 2025-05-30 | Douglas G Evans | Director | A | +7,950 | — |
| 2025-04-02 | Megan Smeykal | Chief Accounting Officer | F | −96 | −$117 |
| 2025-04-02 | Paul Talmo | Chief Technology Officer | F | −190 | −$232 |
| 2025-04-02 | Antony Koblish | Chief Executive Officer | F | −384 | −$468 |
| 2025-04-02 | Gregory A. Firestone | Chief Commercial Officer | F | −119 | −$145 |
| 2025-02-25 | Roberto Cuca | COO and CFO | MIXED | +51,766 | −$14.24K |
| 2025-02-25 | Paul Talmo | Chief Technology Officer | MIXED | +32,990 | −$13.83K |
| 2025-02-25 | Gregory A. Firestone | Chief Commercial Officer | MIXED | +49,644 | −$5.30K |
| 2025-02-25 | Megan Smeykal | Chief Accounting Officer | F | −2,552 | −$6.90K |
| 2025-02-25 | Antony Koblish | Chief Executive Officer | MIXED | +131,597 | −$46.93K |
| 2025-02-21 | Megan Smeykal | Chief Accounting Officer | A | +9,400 | — |
| 2024-10-24 | Gregory A. Firestone | Chief Commercial Officer | Buy | +6,666 | +$15.00K |
| 2024-10-24 | Paul Talmo | Chief Technology Officer | Buy | +22,222 | +$50.00K |
| 2024-10-24 | Antony Koblish | Chief Executive Officer | Buy | +88,888 | +$200.00K |
| 2024-10-24 | Roberto Cuca | COO and CFO | Buy | +64,444 | +$145.00K |
| 2024-08-06 | Gregory A. Firestone | Chief Commercial Officer | F | −1,093 | −$4.65K |
| 2024-07-02 | OrbiMed Capital GP IV LLC | 10%+ Owner | Sell | −856,600 | −$4.04M |
| 2024-06-06 | Douglas G Evans | Director | A | +4,250 | — |
| 2024-06-06 | Kurt Azarbarzin | Director | A | +4,250 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| EW HEALTHCARE PARTNERS FUND 2-A, L.P. | 10%+ Owner | 9,106,477 | $8.94M |
| Antony Koblish | Chief Executive Officer | 766,110 | $751.94K |
| Heather C Getz | Chief Executive Officer | 532,500 | $522.65K |
| Kurt Azarbarzin | Director | 299,260 | $293.72K |
| Roberto Cuca | COO and CFO | 262,611 | $257.75K |
| Jeffrey Blizard | President | 205,125 | $201.33K |
| Joseph H Capper | Director | 199,628 | $195.93K |
| Paul Talmo | Chief Technology Officer | 180,882 | $177.54K |
| Gregory A. Firestone | Chief Business Officer | 139,307 | $136.73K |
| Megan Smeykal | Chief Accounting Officer | 69,681 | $68.39K |
| William J. Plovanic | Director | 60,619 | $59.50K |
| Betty Jo Rocchio | Director | 23,600 | $23.16K |
| Guy P Nohra | Director | 23,600 | $23.16K |
| Paul Thomas | Director | 23,600 | $23.16K |
| Vincent J Burgess | Director | 23,330 | $22.90K |
| Douglas G Evans | Director | 18,470 | $18.13K |
| Lisa N Colleran | Director | 18,470 | $18.13K |
| Federica F. O'Brien | Director | 18,470 | $18.13K |
| Guido J Neels | Director | 11,925 | $11.70K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TELA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.